Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy BioLineRx stock | $2.86

Learn how to easily invest in BioLineRx stock.

BioLineRx Ltd is a biotechnology business based in the US. BioLineRx shares (BLRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioLineRx employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in BioLineRx

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BLRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BioLineRx stock price (NASDAQ: BLRX)

Use our graph to track the performance of BLRX stocks over time.

BioLineRx shares at a glance

Information last updated 2021-10-25.
Latest market close$2.86
52-week range$1.40 - $4.23
50-day moving average $2.77
200-day moving average $2.94
Wall St. target price$14.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.10

Buy BioLineRx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioLineRx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioLineRx price performance over time

Historical closes compared with the close of $2.86 from 2021-10-26

1 week (2021-10-20) 2.86
1 month (2021-09-28) 5.54%
3 months (2021-07-28) -12.80%
6 months (2021-04-28) -7.74%
1 year (2020-10-27) 94.56%
2 years (2019-10-25) 7.12%
3 years (2018-10-26) 290.02%
5 years (2016-10-27) 180.39%

Is BioLineRx under- or over-valued?

Valuing BioLineRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLineRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioLineRx's PEG ratio

BioLineRx's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLineRx's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioLineRx financials

Gross profit TTM $0
Return on assets TTM -19.47%
Return on equity TTM -65.24%
Profit margin 0%
Book value $1.59
Market capitalisation $136.2 million

TTM: trailing 12 months

Shorting BioLineRx shares

There are currently 206,120 BioLineRx shares held short by investors – that's known as BioLineRx's "short interest". This figure is 8.5% up from 190,035 last month.

There are a few different ways that this level of interest in shorting BioLineRx shares can be evaluated.

BioLineRx's "short interest ratio" (SIR)

BioLineRx's "short interest ratio" (SIR) is the quantity of BioLineRx shares currently shorted divided by the average quantity of BioLineRx shares traded daily (recently around 307641.79104478). BioLineRx's SIR currently stands at 0.67. In other words for every 100,000 BioLineRx shares traded daily on the market, roughly 670 shares are currently held short.

However BioLineRx's short interest can also be evaluated against the total number of BioLineRx shares, or, against the total number of tradable BioLineRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioLineRx's short interest could be expressed as 0% of the outstanding shares (for every 100,000 BioLineRx shares in existence, roughly 0 shares are currently held short) or 0.0045% of the tradable shares (for every 100,000 tradable BioLineRx shares, roughly 5 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioLineRx.

Find out more about how you can short BioLineRx stock.

BioLineRx share dividends

We're not expecting BioLineRx to pay a dividend over the next 12 months.

Have BioLineRx's shares ever split?

BioLineRx's shares were split on a 1:15 basis on 14 July 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLineRx shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for BioLineRx shares which in turn could have impacted BioLineRx's share price.

BioLineRx share price volatility

Over the last 12 months, BioLineRx's shares have ranged in value from as little as $1.4 up to $4.23. A popular way to gauge a stock's volatility is its "beta".

BLRX.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLineRx's is 1.4531. This would suggest that BioLineRx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

BioLineRx overview

BioLineRx Ltd. , a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Frequently asked questions

What percentage of BioLineRx is owned by institutions?
Currently 15.702% of BioLineRx shares are held by institutions.
How many people work for BioLineRx?
Latest data suggests 38 work at BioLineRx.
When does the fiscal year end for BioLineRx?
BioLineRx's fiscal year ends in December.
Where is BioLineRx based?
BioLineRx's address is: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
What is BioLineRx's ISIN number?
BioLineRx's international securities identification number is: US09071M2052
What is BioLineRx's CUSIP number?
BioLineRx's Committee on Uniform Securities Identification Procedures number is: 09071M106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site